Fludarabine

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

Size Price Stock Quantity  
In DMSO USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Br J Cancer, 2018, 118(4):509-521. Fludarabine purchased from Selleck.

    ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

  • Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

    Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

  • Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  NXfmUoZsTnWwY4Tpc44hSXO|YYm= MVSyNEDPxE1? MV[yOEBp NVvBdYdVcW6qaXLpeJMh\XiycnXzd4lwdiCxZjDJSG8> MVSyOVk1ODdzMh?=
MV-4-11 NFXQVY1CeG:ydH;zbZMhSXO|YYm= NXPJSGlxOi53IN88US=> MUC0PEBp MmW2bY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NWTncGVLOjVzMUG1PFM>
THP-1 MYPBdI9xfG:|aYOgRZN{[Xl? Mny0Nk42KM7:TR?= NWKzR4N2PDhiaB?= MXTpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NXjiZnFGOjVzMUG1PFM>
MOLM 13 MWPBdI9xfG:|aYOgRZN{[Xl? MX2yMlUh|ryP MV60PEBp MmW5bY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NXr2S5c1OjVzMUG1PFM>
KBM3/Bu2506 M{ftNmFxd3C2b4Ppd{BCe3OjeR?= NFXmZZczNjVizszN MXe0PEBp MV7pcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MVWyOVEyOTV6Mx?=
Nalm-6 NWXOdnIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF6IN88US=> NUDmWYM5OjVyNkGxNFE>
Reh M1;3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTNyIN88US=> NXniWVFxOjVyNkGxNFE>
U2937 NV;HOYZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vYcmlEPTB;MU[g{txO MXKyOVA3OTFyMR?=
Mec-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rhc2lEPTExvK61NFAh|ryP M1X5SFI2ODZzMUCx
RPMI-8226 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTVyMDFOwG0> M3vqclI2ODZzMUCx
Molt-4 NF7NSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PlTmlEPTB;MUiwJO69VQ>? MnS0NlUxPjFzMEG=
Nalm-6-FluR NGi3bYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ3MDFOwG0> NGDj[3ozPTB4MUGwNS=>
Raji  M4PtfGZ2dmO2aX;uJGF{e2G7 MV6zxsDPxE1? MV[yOE81QC95MjDo NX\uZYk4cW6mdXPld{Bi[2O3bYXsZZRqd26|IH;mJJA2OyxicE[zJIFv\CCyN{RCpC=> MXuyOFk1ODZ7NR?=
PBMC NUjQTo8{TnWwY4Tpc44hSXO|YYm= M2nUflUxNzFyMDFOwG0> M3rJ[VI1KGh? NX2zUYxNTE2VTx?= MoXLbY5pcWKrdIOgV3RCXDFicHjvd5Bpd3K7bHH0bY9v NGXDfpQzPDlzMUi3Ni=>
MDA-231 M1LjSGZ2dmO2aX;uJGF{e2G7 M3TmfFExOCEQvF2= MU[yOEBp MnWzSG1UVw>? MmG4[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w NYfYUIlTOjR7MUG4O|I>
624.38mel  NVLINYE3TnWwY4Tpc44hSXO|YYm= NHXx[242OCEQvF2= NUn5R24{OjRiaB?= M1\NOmROW09? MnfO[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w MlvRNlQ6OTF6N{K=
MDA-231 NIrYd2pHfW6ldHnvckBCe3OjeR?= M1TmblUxNTJyMDFOwG0> MmThNlQhcA>? NYrE[IV{TE2VTx?= M1jPT4lvcGmkaYTzJGlFVyCjY4Tpeol1gSCrbnTldIVv\GWwdHz5JI9nKG2UTlGgcIV3\Wy| MVKyOFkyOTh5Mh?=
624.38mel  MkHsSpVv[3Srb36gRZN{[Xl? MUG1NE0zODBizszN M4exdFI1KGh? NHT4OYFFVVOR MnrXbY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN? M4DUTlI1QTFzOEey
HMECs MX7GeY5kfGmxbjDBd5NigQ>? M{\Mc|ExOMLizszNxsA> MYOzOuKhcA>? MmXGbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> Ml3KNlQzOTF|Mke=
HMECs  MnmzSpVv[3Srb36gRZN{[Xl? MoLmNVAxyqEQvF5CpC=> M4nwPVM3yqCq NGDBSFhqdmirYnn0d{BKTk8QsdMgcYVlcWG2ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNVSVRzIHHu[EBUXEGWMzygZpV1KG6xdDDv[kBUXEGWMh?= MmrJNlQzOTF|Mke=
BJAB M1PiOWFxd3C2b4Ppd{BCe3OjeR?= MlnFOeKh|ryP MofWNlQhcA>? M3vkTIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnfjNlQxPTdzNEe=
I-83 NFzUWnlCeG:ydH;zbZMhSXO|YYm= MmS5OeKh|ryP Ml:5NlQhcA>? M4HseYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXvBSHExOjRyNUexOFc>
NALM6 MlTaRZBweHSxc3nzJGF{e2G7 MVe1xsDPxE1? MmTUNlQhcA>? NIX2S3ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3HB[|I1ODV5MUS3
DU-145 M2fYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnUTWhzOC1zMDFOwIcwdWx? NFHNN|Y1QCCqwrC= Mk\1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mn;XNlM4OzR6MUW=
Nalm-6 NXfrZXZyTnWwY4Tpc44hSXO|YYm= M4KyNFExyqEQvF2= NGezcnYyNzJxNDDo M3TuTolv\HWlZYOgZZV1d3CqYXf5 NEXQRokzOzZ6MUKyNy=>
Reh MX3GeY5kfGmxbjDBd5NigQ>? MVixNOKh|ryP MUCxM|IwPCCq NH65RphqdmS3Y3XzJIF2fG:yaHHnfS=> M3;5Z|I{PjhzMkKz
Nalm-6 Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDydXpqUUN3MDFijNwyOOLCid88US=> M33weFI{PjhzMkKz
Reh M3XWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxKOLKvEGw5qCK|ryP M1TU[lI{PjhzMkKz
HEC1A NVH6bYpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuxNFAuPTByIN88US=> M{HMO|I1KGh? MlXvbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnLZNlM2QTV4OUe=
AN3CA MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknDNVAxNTVyMDFOwG0> NGHrSHEzPCCq NHnLXYlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoLzNlM2QTV4OUe=
HEC50B MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWxNFAuPTByIN88US=> NXr0NHRKOjRiaB?= M13HcIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 NVfORWh1OjN3OUW2PVc>
HEC1A NIXJeI9CeG:ydH;zbZMhSXO|YYm= NIXCcWIzOC9zMECg{txO MkfpNlQhcA>? NHrhepdqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGPqNWszOzV7NU[5Oy=>
AN3CA M3\YRWFxd3C2b4Ppd{BCe3OjeR?= MYKyNE8yODBizszN MlLJNlQhcA>? NVrCSVRtcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1XydFI{PTl3Nkm3
HEC50B M3PzcmFxd3C2b4Ppd{BCe3OjeR?= MX[yNE8yODBizszN NGrPWWozPCCq NGfaUGRqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NIDOUFQzOzV7NU[5Oy=>
EHEB M1\mN2Fxd3C2b4Ppd{BCe3OjeR?= NIK5fHQ1OCEQvF2= M4XydlI1KGh? MkezbY5lfWOnczDhdI9xfG:|aYO= NVuwOnBwOjN2OUewO|U>
A549 M{XNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH0TWM2OD1zNT63xtEzNjhiwsXN NI\NeGIzOzN5N{G5Ni=>
A549 GAPDH-deficient NGrUd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF6LkZCtVIvOyEEtV2= MnfrNlM{PzdzOUK=
CLL  MVjBdI9xfG:|aYOgRZN{[Xl? NGjWO4kyOCEQvF5CpC=> NFrmdogzPC17NjDo MUTpcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo MoPONlIzODd4OE[=
MEC1 NVHqcZdqSXCxcITvd4l{KEG|c3H5 MkTINVAxyqEQvF2= MV:3NkBp Mn7JbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? M4\WZ|IzOTN{OUez
U937  MUnBdI9xfG:|aYOgRZN{[Xl? NFXxPJAxNjhizszN NVTKOFczPC12ODDo NH3KZ2NqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> M3jEd|IzODd2N{Cw
U937  NEi1cVBCeG:ydH;zbZMhSXO|YYm= M36xUlEh|ryP MXO5OkBp M2j1PYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NYCy[HRNOjJyMkO1NlM>
Daudi NXqwdVBSSXCxcITvd4l{KEG|c3H5 MXyyNEDPxE1? NUS0fGhoQTZiaB?= NH;RcmZqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> M2S4cVIzODJ|NUKz
J45.01 NXTIZoRUSXCxcITvd4l{KEG|c3H5 MWSxJO69VQ>? NVzYeGRRQTZiaB?= M4HpbYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NXHHUYJROjJyMkO1NlM>
RPMI 8226 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn64TWM2OD1{NT65xsDDucLiMz63JO69VQ>? NUDi[npuOjF7NEiyOlQ>
CEM NILYNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXzSVdKSzVyPUKuOOKhyrIEoECuOEDPxE1? MWGyNVk1QDJ4NB?=
Raji M4nIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnHT3VHUUN3ME2wMlQ4yqEEsdMgNE4xPCEQvF2= NVPJcmtTOjF7NEiyOlQ>
U937 M4nX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\RTWM2OD1yLkK0xsDDucLiMD6wOEDPxE1? MnK0NlE6PDh{NkS=
K562 M2TjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3e0e2lEPTB;MD60OOKhyrIEoECuNFUh|ryP NGPXWW8zOTl2OEK2OC=>
NALM-6 NF;he5pCeG:ydH;zbZMhSXO|YYm= MWexNEDPxE4EoB?= MVqyOEBp MWfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOuaXfoeIx6 NWjaNHhzOjF4OUmzPFM>
JMV-3 M3TOTWFxd3C2b4Ppd{BCe3OjeR?= MojaNVAh|ryPwrC= M3LMS|I1KGh? MoS2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|bHnnbJRtgQ>? MmXPNlE3QTl|OEO=
EHEB M3i5cWZ2dmO2aX;uJGF{e2G7 MnS1OU02OCEQvF2= MX6yOEBp Mkfm[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> NIO3XG4zOTF4OEO5NS=>
JVM-2  MmfISpVv[3Srb36gRZN{[Xl? NH\5RZg{OCEQvF2= M3v5XFI1KGh? M{DjRYRm[3KnYYPld{BxOjFiZYjwdoV{e2mxbh?= NIHZ[2czOTF4OEO5NS=>
KBM3/Bu2506 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED4bpJKSzJyPUCuOlchyrWP M1\3V|IxQTN|NUC5
KBM3/Bu2506 NUD1eZAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHFXnExNjZizszN MVeyOEBp NYHVR2xxcW6lcnXhd4V{KHSqZTDj[YxtKG[{YXP0bY9vKGmwIGOtdIhie2V? Mn;XNlA6OzN3MEm=
MDA-MB-231 M3PUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzuT2ZKSzVyPUSuNEDPxE1? NW\YWVFMOjB2NEezPVA>
MCF-7 NHXUfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF3LkCg{txO NYryeWFwOjB2NEezPVA>
HLE-B3  NH\EOVBHfW6ldHnvckBCe3OjeR?= MWCyOUDPxE1? NEO3OHE1QCCq NX2wXItC[myxY3vzJGlHVi4Qs,MAl4lv\HWlZXSgV3RCXDFicHjvd5Bpd3K7bHH0bY9vKGGwZDDJSG8h\XiycnXzd4lwdg>? NWD4RXU3OjB2M{WxOVg>
K562 M37iPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jFTVczKGh? MmLzTWM2OD1|LkOgcm0> M{TaNVIxOzB5MUm4
BW-225 NVmxeHNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|IxRTFwM{egx7cyOOLKkklCpO69VcLi Ml\pNVg3PjF|OEC=
OH-65 NGC1WG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH73WmJKSzJyPUGuN|chy5dzMPMIlljDqM7:TdMg MWCxPFY3OTN6MB?=
GR-145 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|IxRTJwN{Sgx7chOTEkiKK4JEDPxE4EoB?= NWL6N|h[OTh4NkGzPFA>
A549 NXrnWohST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|IxRTVwNEigx7chOTEkiKK4JO69VcLi MlzpNVg3PjF|OEC=
CaSki  NE\JUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjJOYo5UUN{ME2xMlM4KMPZIEGw5qiTPyEQvF5CpC=> NWWzRYl3OTh4NkGzPFA>
ZMK-1 M4SyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXPNWJKSzJyPUGuN|chy5diMUFijLI3KM7:TdMg M1uxUVE5PjZzM{iw
SKW6.4 Mlr2RZBweHSxc3nzJGF{e2G7 M{jKdlAvODFvMUCg{txO Mn;vNlQwPDhiaB?= NH3vWItqdmS3Y3XzJINmdGxiZHXheIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= NFWzTXEyQDB7MkO0NC=>
RPMI 8226 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoewNlQhcA>? MWjJR|UxRTFwNUVCpO69VQ>? NWXVSZU{OTd7N{[xPFY>
MM.1S M{jWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPWOFghcA>? MWrJR|UxRTF|LkS4xsDPxE1? MX:xO|k4PjF6Nh?=
MM.1R NYnwWlVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW0PEBp MVPJR|UxRTN|Lke5JO69VQ>? NWe5WlRHOTd7N{[xPFY>
U937 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\lTWM2OD1|LEKwNEDDuSB3NkCgcm0> MWqxOVk{ODN4MR?=

... Click to View More Cell Line Experimental Data

In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Formulation: PBS
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01503242 Active not recruiting Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) January 9 2012 Phase 1
NCT03159702 Recruiting Hematological Malignancy Undergoing a Related Donor Haploidentical HCT|Leukemia|Multiple Myeloma|Lymphoma Medical College of Wisconsin December 8 2017 Phase 2
NCT03333486 Recruiting Accelerated Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|Aplastic Anemia|B-Cell Non-Hodgkin Lymphoma|CD40 Ligand Deficiency|Chronic Granulomatous Disease|Chronic Leukemia in Remission|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Congenital Amegakaryocytic Thrombocytopenia|Congenital Neutropenia|Congenital Pure Red Cell Aplasia|Glanzmann Thrombasthenia|Immunodeficiency Syndrome|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Paroxysmal Nocturnal Hemoglobinuria|Plasma Cell Myeloma|Polycythemia Vera|Recurrent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Severe Aplastic Anemia|Shwachman-Diamond Syndrome|Sickle Cell Disease|T-Cell Non-Hodgkin Lymphoma|Thalassemia|Waldenstrom Macroglobulinemia|Wiskott-Aldrich Syndrome Roswell Park Cancer Institute|National Cancer Institute (NCI) December 7 2017 Phase 2
NCT00448201 Completed Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) January 7 2011 Phase 2
NCT00474747 Completed Aplastic Anemia M.D. Anderson Cancer Center|National Heart Lung and Blood Institute (NHLBI)|National Cancer Institute (NCI) February 7 2006 Phase 1|Phase 2
NCT03494569 Recruiting Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia|Acute Myeloid Leukemia in Remission|Hematopoietic Cell Transplantation Recipient|Minimal Residual Disease|Myelodysplastic Syndrome|Secondary Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) July 6 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products0

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID